Supernus Pharmaceuticals reported $14.72M in Pre-Tax Profit for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Abbott ABT:US $ 3899M 1051M
Bristol Myers Squibb BMY:US $ 5386M 595M
Canopy Growth Corp WEED:CN C$ -587071000 471.39M
Cara Therapeutics CARA:US $ -27749000 5.63M
Eisai 4523:JP Y -20779M 34669M
JAZZ PHA JAZZ:US $ 321.29M 19.04M
Marinus Pharmaceuticals MRNS:US $ -19.36M 8.94M
Pacira Pharmaceuticals PCRX:US $ 39.79M 19.7M
Pfizer PFE:US $ 11328M 4083M
Revance Therapeutics RVNC:US $ -64.34M 1.24M
Supernus Pharmaceuticals SUPN:US $ 14.72M 12.67M
Teva Pharmaceutical Industries TEVA:US $ 766M 253M
United Therapeutics UTHR:US $ 308.7M 168.2M
Xeris Pharmaceuticals Inc XERS:US $ -34122000 16.67M